Global Blood Therapeutics (GBT): Raising PT After Formation Of Pivotal Sickle Cell Study - Wedbush

October 25, 2016 7:11 AM EDT
Get Alerts GBT Hot Sheet
Price: $16.70 +1.52%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade GBT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush analyst, Heather Beananna reiterated her Outperform rating on Global Blood Therapeutics (NASDAQ: GBT) and raised her price target to $73 from $66.

Global Blood announced the design of its pivotal study (HOPE) for GBT440 in sickle cell disease (SCD) patients. The trial design represents a best case scenario - the company avoids a long, risky VOC study, and instead, it can pursue a study with a hematologic primary endpoint and a key secondary endpoint that will likely be a patient reported outcome of pain or fatigue. The FDA buy-in with the clinical plan supports the agency's interest in helping sickle cell patients and buy-in with GBT440 data. The pivotal study is expected to begin in December with data expected in 1H19.

The analyst sees a lower risk regulatory path and an increase in news flow over the coming two years. The next fundamental catalyst for GBT shares is 900mg 90 day data at ASH.

For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.

Shares of Global Blood Therapeutics closed at $17.75 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment